| Literature DB >> 18653247 |
Isabel Illa1, Jordi Diaz-Manera, Ricard Rojas-Garcia, Jesus Pradas, Antonio Rey, Rafael Blesa, Candido Juarez, Eduard Gallardo.
Abstract
We report the results of treatment with Rituximab in six severe, non-responder MG patients. We treated three AChR+MG and three MuSK+MG patients, representing 2% and 20% of the respective groups of our series. Patients were assessed according to the Myasthenia Gravis Foundation of America (MGFA) recommendations. Antibody titers to AChR and MuSK, Ig levels, and IgG subclasses, were tested before treatment and during a follow-up of 9-22 months. All patients, one class V and five class IVB, improved dramatically, with no side effects. Antibody titers declined in all patients (p=0.006). The decline was significantly better in MuSK+MG patients at 9 months (p=0.046) and correlated with a more sustained clinical improvement. We did not find any significant changes in IgG4 that could explain the different outcome observed between these two groups.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18653247 DOI： 10.1016/j.jneuroim.2008.04.039
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478